Please login first
Jean Guillon   Professor  Senior Scientist or Principal Investigator 
Timeline See timeline
Jean Guillon published an article in November 2018.
Research Keywords & Expertise
0 A
0 Leukemia
0 Synthesis
0 Protein
0 µm
Top co-authors See all
Holger Gohlke

187 shared publications

Institute of Pharmaceutical and Medicinal Chemistry

Susan Costantini

118 shared publications

Unità di Farmacologia Sperimentale, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy

Valérie Gabelica

116 shared publications

Laboratoire Acides Nucléiques: Régulations Naturelle et Artificielle, Université de Bordeaux, Inserm & CNRS (ARNA, U1212, UMR5320), IECB, 2 rue Robert Escarpit, 33607 Pessac, France

Giovanni Colonna

80 shared publications

Medical Informatics Service, University Hospital, University of Campania ‘Luigi Vanvitelli’, I-80131 Naples, Italy

Marc Le Borgne

79 shared publications

Université de Lyon, Université Lyon 1, Faculté de Pharmacie-ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453-INSERM US7, CEDEX 8, 69373 Lyon, France.

Publication Record
Distribution of Articles published per year 
(2014 - 2018)
Total number of journals
published in
Publications See all
Article 1 Read 0 Citations Crystal structure and identification of a pyrimido[6,1-b][1,3]oxazin-6-one derivative from the reaction of acrolein with... Jean Guillon, Sandra Rubio, Solène Savrimoutou, François Hal... Published: 01 November 2018
Comptes Rendus Chimie, doi: 10.1016/j.crci.2018.09.013
DOI See at publisher website ABS Show/hide abstract
The X-ray crystal structure of 2-(4,5-dihydro-5-phenoxymethyl-1,3-oxazol-2-ylamino)-7-(2-hydroxy-3-phenoxypropyl)hexahydro-2H,6H-pyrimido[6,1-b][1,3]oxazin-6-one (1), a structure of adduct formed by the reaction of 5-(phenoxymethyl)-2-amino-2-oxazoline and acrolein, has been established. The present work deals with the structural identification of the adduct 1 and presents a plausible mechanism for its formation. It crystallizes in the monoclinic space group P21/c with cell parameters a = 21.3337 (10) Å, b = 11.3712 (7) Å, c = 10.4936 (7) Å, β = 103.041 (3), V = 2480.0 (3) Å3, Z = 4. C26H32N4O6, Dc = 1.330 g/cm3, μ (Cu Kα) = 1.5418 Å, S = 1.188, F (000) = 1056, R = 0.0501, and wR = 0.1584. La structure complète de la 2-(4,5-dihydro-5-phénoxymethyl-1,3-oxazol-2-ylamino)-7-(2-hydroxy-3-phénoxypropyl)hexahydro-2H,6H-pyrimido[6,1-b][1,3]oxazin-6-one 1, une structure d'adduit formée lors de la réaction de la 5-(phénoxyméthyl)-2-amino-2-oxazoline et de l'acroléine, a été établie sans équivoque par une analyse cristallographique aux rayons X. Le présent travail porte sur l'identification structurale de l'adduit 1 et présente un mécanisme plausible pour sa formation. La molécule cristallise dans le système monoclinique, dans le groupe spatial P21/c avec a = 21.3337 (10) Å, b = 11.3712 (7) Å, c = 10.4936 (7) Å, β = 103.041 (3), V = 2480.0 (3) Å3, Z = 4. C26H32N4O6, Dc = 1.330 g/cm3, μ (Cu Kα) = 1.5418 Å, S = 1.188, F (000) = 1056, R = 0.0501 et wR = 0.1584.
Article 2 Reads 0 Citations 1-Methyl-3-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-2-phenylindole Jean Guillon, Solène Savrimoutou, Sandra Rubio, Vanessa Desp... Published: 04 October 2018
Molbank, doi: 10.3390/m1023
DOI See at publisher website ABS Show/hide abstract
The 1-methyl-3-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-2-phenylindole compound has been successfully synthesized via a multistep pathway starting from 2-phenylindole. Structure characterization of this new indole derivative was done by FTIR, 1H-NMR, 13C-NMR, and HRMS spectral analysis. The title compound showed high cytotoxic potential against five leukemia cell lines (K562, HL60, U937, U266, and Jurkat cell lines).
Article 0 Reads 0 Citations Synthesis, Crystal Structure and Anti-leukemic Activity of 4-{4-[(4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-... Jean Guillon, Stéphane Moreau, Vanessa Desplat, Marian Vince... Published: 17 September 2018
Journal of Chemical Crystallography, doi: 10.1007/s10870-018-0734-2
DOI See at publisher website
Article 0 Reads 1 Citation Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline deri... Jean Guillon, Anita Cohen, Rabindra Nath Das, Clotilde Boudo... Published: 17 January 2018
Chemical Biology & Drug Design, doi: 10.1111/cbdd.13164
DOI See at publisher website PubMed View at PubMed
Article 0 Reads 3 Citations Synthesis and Antiproliferative Effect of Ethyl 4-[4-(4-Substituted Piperidin-1-yl)]benzylpyrrolo[1,2-a ]quinoxalinecarb... Vanessa Desplat, Marian Vincenzi, Romain Lucas, Stéphane Mor... Published: 05 April 2017
ChemMedChem, doi: 10.1002/cmdc.201700049
DOI See at publisher website PubMed View at PubMed
Article 0 Reads 1 Citation Design, synthesis and antimalarial activity of novel bis{ N -[(pyrrolo[1,2- a ]quinoxalin-4-yl)benzyl]-3-aminopropyl}ami... Jean Guillon, Anita Cohen, Nassima Meriem Gueddouda, Rabindr... Published: 23 January 2017
Journal of Enzyme Inhibition and Medicinal Chemistry, doi: 10.1080/14756366.2016.1268608
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Novel series of bis- and tris-pyrrolo[1,2-a]quinoxaline derivatives 1 were synthesized and tested for in vitro activity upon the intraerythrocytic stage of W2 and 3D7 Plasmodium falciparum strains. Biological results showed good antimalarial activity with IC50 in the μM range. In attempting to investigate the large broad-spectrum antiprotozoal activities of these new derivatives, their properties toward Leishmania donovani were also investigated and revealed their selective antiplasmodial profile. In parallel, the in vitro cytotoxicity of these molecules was assessed on the human HepG2 cell line. Structure-activity relationships of these new synthetic compounds are discussed here. The bis-pyrrolo[1,2-a]quinoxalines 1n and 1p were identified as the most potent antimalarial candidates with selectivity index (SI) of 40.6 on W2 strain, and 39.25 on 3D7 strain, respectively. As the telomeres of the parasite could constitute an attractive target, we investigated the possibility of targeting Plasmodium telomeres by stabilizing the Plasmodium telomeric G-quadruplexes through a FRET melting assay by our new compounds.
Conference papers
CONFERENCE-ARTICLE 25 Reads 0 Citations Synthesis and Evaluation of New 6-formyl-oxazolo[3,2-a]pyrimidine derivatives as Potential Src Kinase Inhibitors Jean Guillon, François Hallé, Solène Savrimoutou, Stéphane M... Published: 31 October 2018
doi: 10.3390/ecmc-4-05566
DOI See at publisher website ABS Show/hide abstract

The tyrosine-protein kinase Src, also known as proto-oncogene c-Src or simply c-Src, is a non-receptor tyrosine kinase protein that has been shown to be involved in the regulation of important cellular processes including migration, survival and proliferation. In fact, Src activation has been associated with multiple cancers, such as colon, breast, pancreas, lung, or brain (Roskoski, R. Jr. Pharmacol. Res. 2015, 94, 9-25; Creedon, H., et al., Crit. Rev. Oncog. 2012, 17, 145-159). There are only few Src inhibitors in clinical development, therefore, there is an urgent need to identify new low molecular weight therapeutics able to inhibit Src and, thus, to modulate aberrant pathways leading to malignant transformation of cells (Lu, X.L., et al., Curr. Med. Chem. 2012, 19, 1821-1829). Heterocyclic compounds attracted a lot of attention because of their wide spread biological activities. Thus, we have previously reported the synthesis of biological active heterocyclic derivatives based on the reactivity of the amidine moiety of 2-amino-2-oxazolines 2 with bis-electrophiles (Massip, S., et al., Bioorg. Med. Chem. 2006, 14, 2697-2719).

In a preliminary screening testing our heterocycles library, we have identified a “hit” (compound 1d) derived from various substituted 6-formyl-oxazolo[3,2-a]pyrimidines as a new Src kinase inhibitor (IC50 = 4 µM). These original oxazolo[3,2-a]pyrimidine derivatives 1a-k were synthesized through a Diels-Alder cycloaddition of alkylidene derivatives of 2-amino-2-oxazoline (compounds 3a-k) with acrolein, as an electron-poor dienophile, a reaction previously described by our group (Guillon, J., et al., Synlett 2002, 8, 1249-1252). Versatility given by this reaction allowed us to access a promising family of diversely substituted 6-formyl-oxazolo[3,2-a]pyrimidines with inhibitory effect on Src kinase.

Acknowledgments: This work was supported by a grant from Ligue Contre le Cancer (Gironde, Bordeaux, France).